Dengue is a mosquito-borne viral disease and one of the fastest-spreading vector-borne illnesses globally. The World Health Organization reported a record 14.4 million dengue cases and 11,201 deaths worldwide in 2024, including 232,425 cases and 233 deaths in India.
The company said it expects Qdenga to become available in India in the first half of 2027, after market authorization, with initial availability through private healthcare settings.
Also read | A 1989 deal returns to haunt Tata Trusts as Noel Tata gets notice
“We are progressing well and remain on track toward our goal of reaching a global manufacturing capacity of 100 million doses per year by 2030,” the company said while reaffirming its partnership with Indian vaccine maker Biological E to boost Qdenga’s expansion as the tie-up looks to support production of up to 50 million doses annually.
Reported dengue cases in India rose 11-fold in the past two decades, according to Takeda Biopharmaceuticals India.
Qdenga, designed to protect against all four dengue virus serotypes, is indicated for the prevention of dengue in children and adults aged 4 to 60 years, the company said.In a late-stage trial, the vaccine, approved in 43 countries so far, showed an efficacy of 80.2% against confirmed dengue cases one year after the second dose.
Also read | Taxman looks to ease GST burden for India Inc
It also showed 90.4% efficacy against dengue-related hospitalizations after 18 months, meeting the secondary end-point of the study, according to the company.
Takeda India had partnered with Indian vaccine maker Biological E in 2024 to expand the drug’s manufacturing.
LENGTHY PROCESS
Qdenga is administered as a two-dose, 0.5 ml injection given three months apart and can be used regardless of prior dengue exposure, eliminating the need for pre-vaccination testing.
This differs from Sanofi’s Dengvaxia, which is not approved in India and is recommended only for people with prior dengue infection due to concerns about an increased risk of severe dengue in some without previous exposure to the virus, said Divya K.S., an infectious diseases specialist at Apollo Hospitals.
Regulators may have required additional post-marketing safety data before granting approval, according to Divya.
“Qdenga can help reduce disease severity and hospitalizations, but it is unlikely to prevent outbreaks as long as the mosquito vector continues to circulate, she said.
The lengthy development process for dengue vaccines remains a challenge for other vaccine makers as well.
Hyderabad-based Indian Immunologicals Ltd (IIL), which is developing a dengue vaccine candidate of its own, is preparing to begin mid-stage clinical trials, Managing Director K. Anand Kumar told Reuters separately.
“Addressing safety concerns arising from earlier dengue vaccines and identifying trial participants who have not previously been infected with dengue or related viruses takes time,” Kumar said.